

Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

Information for the public Published: 27 February 2019

www.nice.org.uk

Encorafenib with binimetinib is available on the NHS as a possible treatment, in adults, for melanoma that:

- can't be removed by surgery or has spread to other parts of the body, and
- has the BRAF V600 mutation.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about <u>making decisions about your care</u>.

Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The <u>NHS website</u> may be a good place to find out more.

These organisations can give you advice and support:

- <u>Melanoma UK</u>, 0808 171 2455
- <u>Melanoma Focus</u>, 0808 801 0777
- Macmillan Cancer Support, 0808 808 0000
- Cancer Research UK, 0808 8800 4040

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3277-1